Exhibit 10.1
UNITED STATES DEPARTMENT OF THE
TREASURY
1500 PENNSYLVANIA AVENUE,
NW
WASHINGTON, D.C. 20220
Dear Ladies and
Gentlemen:
The company set forth on the
signature page hereto (the “ Company ”)
intends to issue in a private placement the number of shares of a
series of its preferred stock set forth on Schedule A hereto (the
“ Preferred Shares ”) and a warrant to purchase
the number of shares of its common stock set forth on Schedule A
hereto (the “ Warrant ” and, together with the
Preferred Shares, the “Purchased Securities”) and the
United States Department of the Treasury (the “
Investor ”) intends to purchase from the Company the
Purchased Securities.
The purpose of this letter agreement
is to confirm the terms and conditions of the purchase by the
Investor of the Purchased Securities. Except to the extent
supplemented or superseded by the terms set forth herein or in the
Schedules hereto, the provisions contained in the Securities
Purchase Agreement – Standard Terms attached hereto as
Exhibit A (the “ Securities Purchase Agreement
”) are incorporated by reference herein. Terms that are
defined in the Securities Purchase Agreement are used in this
letter agreement as so defined. In the event of any inconsistency
between this letter agreement and the Securities Purchase
Agreement, the terms of this letter agreement shall
govern.
Each of the Company and the Investor
hereby confirms its agreement with the other party with respect to
the issuance by the Company of the Purchased Securities and the
purchase by the Investor of the Purchased Securities pursuant to
this letter agreement and the Securities Purchase Agreement on the
terms specified on Schedule A hereto.
This letter agreement (including the
Schedules hereto) and the Securities Purchase Agreement (including
the Annexes thereto) and the Warrant constitute the entire
agreement, and supersede all other prior agreements,
understandings, representations and warranties, both written and
oral, between the parties, with respect to the subject matter
hereof. This letter agreement constitutes the “Letter
Agreement” referred to in the Securities Purchase
Agreement.
This letter agreement may be
executed in any number of separate counterparts, each such
counterpart being deemed to be an original instrument, and all such
counterparts will together constitute the same agreement. Executed
signature pages to this letter agreement may be delivered by
facsimile and such facsimiles will be deemed as sufficient as if
actual signature pages had been delivered.
* * *
In witness whereof, this letter
agreement has been duly executed and delivered by the duly
authorized representatives of the parties hereto as of the date
written below.
|
|
UNITED STATES DEPARTMENT OF
THE
|
|
|
TREASURY
|
|
|
|
|
|
|
|
|
By:
|
/s/ Neel Kashkari
|
|
|
|
Name: Neel Kashkari
|
|
|
|
Title: Interim Assistant
Secretary for Financial Stability
|
|
|
|
|
|
|
|
|
OLD SECOND BANCORP,
INC.
|
|
|
|
|
|
|
|
|
By:
|
/s/ J. Douglas Cheatham
|
|
|
|
Name: J. Douglas
Cheatham
|
|
|
|
Title: Executive Vice
President and Chief Financial Officer
|
|
|
|
|
Date: January 16,
2009
|
|
EXHIBIT A
SECURITIES PURCHASE
AGREEMENT
STANDARD TERMS
TABLE OF CONTENTS
|
|
|
Page
|
|
|
|
|
|
|
Article I
|
|
|
|
|
|
|
|
Purchase; Closing
|
|
|
|
|
|
|
1.1
|
Purchase
|
1
|
|
1.2
|
Closing
|
2
|
|
1.3
|
Interpretation
|
4
|
|
|
|
|
|
|
Article II
|
|
|
|
|
|
|
|
Representations and
Warranties
|
|
|
|
|
|
|
2.1
|
Disclosure
|
4
|
|
2.2
|
Representations and Warranties of the
Company
|
5
|
|
|
|
|
|
|
Article III
|
|
|
|
|
|
|
|
Covenants
|
|
|
|
|
|
|
3.1
|
Commercially Reasonable Efforts
|
13
|
|
3.2
|
Expenses
|
14
|
|
3.3
|
Sufficiency of Authorized Common Stock; Exchange
Listing
|
15
|
|
3.4
|
Certain Notifications Until Closing
|
15
|
|
3.5
|
Access, Information and
Confidentiality
|
15
|
|
|
|
|
|
|
Article IV
|
|
|
|
|
|
|
|
Additional Agreements
|
|
|
|
|
|
|
4.1
|
Purchase for Investment
|
16
|
|
4.2
|
Legends
|
16
|
|
4.3
|
Certain Transactions
|
18
|
|
4.4
|
Transfer of Purchased Securities and Warrant
Shares; Restrictions on Exercise of the Warrant
|
18
|
|
4.5
|
Registration Rights
|
19
|
|
4.6
|
Voting of Warrant Shares
|
30
|
|
4.7
|
Depositary Shares
|
31
|
|
4.8
|
Restriction on Dividends and
Repurchases
|
31
|
|
4.9
|
Repurchase of Investor Securities
|
32
|
|
4.10
|
Executive Compensation
|
33
|
|
4.11
|
Bank and Thrift Holding Company
Status
|
33
|
i
|
4.12
|
Predominantly Financial
|
34
|
|
|
|
|
|
|
Article V
|
|
|
|
|
|
|
|
Miscellaneous
|
|
|
|
|
|
|
5.1
|
Termination
|
34
|
|
5.2
|
Survival of Representations and
Warranties
|
35
|
|
5.3
|
Amendment
|
35
|
|
5.4
|
Waiver of Conditions
|
35
|
|
5.5
|
Governing Law: Submission to Jurisdiction,
Etc .
|
35
|
|
5.6
|
Notices
|
35
|
|
5.7
|
Definitions
|
36
|
|
5.8
|
Assignment
|
36
|
|
5.9
|
Severability
|
36
|
|
5.10
|
No Third Party Beneficiaries
|
37
|
ii
LIST OF ANNEXES
|
ANNEX A:
|
FORM OF CERTIFICATE OF DESIGNATIONS FOR
PREFERRED STOCK
|
|
|
|
|
|
|
ANNEX B:
|
FORM OF WAIVER
|
|
|
|
|
|
|
ANNEX C:
|
FORM OF OPINION
|
|
|
|
|
|
|
ANNEX D:
|
FORM OF WARRANT
|
|
iii
INDEX OF DEFINED TERMS
|
Term
|
|
Location of
Definition
|
|
Affiliate
|
|
5.7(b)
|
|
Agreement
|
|
Recitals
|
|
Appraisal Procedure
|
|
4.9(c)(i)
|
|
Appropriate Federal Banking Agency
|
|
2.2(s)
|
|
Bank Holding Company
|
|
4.11
|
|
Bankruptcy Exceptions
|
|
2.2(d)
|
|
Benefit Plans
|
|
1.2(d)(iv)
|
|
Board of Directors
|
|
2.2(f)
|
|
Business Combination
|
|
4.4
|
|
business day
|
|
1.3
|
|
Capitalization Date
|
|
2.2(b)
|
|
Certificate of Designations
|
|
1.2(d)(iii)
|
|
Charter
|
|
1.2(d)(iii)
|
|
Closing
|
|
1.2(a)
|
|
Closing Date
|
|
1.2(a)
|
|
Code
|
|
2.2(n)
|
|
Common Stock
|
|
Recitals
|
|
Company
|
|
Recitals
|
|
Company Financial Statements
|
|
2.2(h)
|
|
Company Material Adverse Effect
|
|
2.1(a)
|
|
Company Reports
|
|
2.2(i)(i)
|
|
Company Subsidiary; Company
Subsidiaries
|
|
2.2(i)(i)
|
|
control; controlled by; under common control
with
|
|
5.7(b)
|
|
Controlled Group
|
|
2.2(n)
|
|
CPP
|
|
Recitals
|
|
EESA
|
|
1.2(d)(iv)
|
|
ERISA
|
|
2.2(n)
|
|
Exchange Act
|
|
2.1(b)
|
|
Fair Market Value
|
|
4.9(c)(ii)
|
|
Federal Reserve
|
|
4.11
|
|
GAAP
|
|
2.1(a)
|
|
Governmental Entities
|
|
1.2(c)
|
|
Holder
|
|
4.5(k)(i)
|
|
Holders’ Counsel
|
|
4.5(k)(ii)
|
|
Indemnitee
|
|
4.5(g)(i)
|
|
Information
|
|
3.5(b)
|
|
Initial Warrant Shares
|
|
Recitals
|
|
Investor
|
|
Recitals
|
|
Junior Stock
|
|
4.8(c)
|
|
knowledge of the Company; Company’s
knowledge
|
|
5.7(c)
|
|
Last Fiscal Year
|
|
2.1(b)
|
iv
|
Term
|
|
Location of
Definition
|
|
Letter Agreement
|
|
Recitals
|
|
officers
|
|
5.7(c)
|
|
Parity Stock
|
|
4.8(c)
|
|
Pending Underwritten Offering
|
|
4.5(l)
|
|
Permitted Repurchases
|
|
4.8(a)(ii)
|
|
Piggyback Registration
|
|
4.5(a)(iv)
|
|
Plan
|
|
2.2(n)
|
|
Preferred Shares
|
|
Recitals
|
|
Preferred Stock
|
|
Recitals
|
|
Previously Disclosed
|
|
2.1(b)
|
|
Proprietary Rights
|
|
2.2(u)
|
|
Purchase
|
|
Recitals
|
|
Purchase Price
|
|
1.1
|
|
Purchased Securities
|
|
Recitals
|
|
Qualified Equity Offering
|
|
4.4
|
|
register; registered; registration
|
|
4.5(k)(iii)
|
|
Registrable Securities
|
|
4.5(k)(iv)
|
|
Registration Expenses
|
|
4.5(k)(v)
|
|
Regulatory Agreement
|
|
2.2(s)
|
|
Rule 144; Rule 144A; Rule 159A;
Rule 405; Rule 415
|
|
4.5(k)(vi)
|
|
Savings and Loan Holding Company
|
|
4.11
|
|
Schedules
|
|
Recitals
|
|
SEC
|
|
2.1(b)
|
|
Securities Act
|
|
2.2(a)
|
|
Selling Expenses
|
|
4.5(k)(vii)
|
|
Senior Executive Officers
|
|
4.10
|
|
Share Dilution Amount
|
|
4.8(a)(ii)
|
|
Shelf Registration Statement
|
|
4.5(a)(ii)
|
|
Signing Date
|
|
2.1(a)
|
|
Special Registration
|
|
4.5(i)
|
|
Stockholder Proposals
|
|
3.1(b)
|
|
subsidiary
|
|
5.8(a)
|
|
Tax; Taxes
|
|
2.2(o)
|
|
Transfer
|
|
4.4
|
|
Warrant
|
|
Recitals
|
|
Warrant Shares
|
|
2.2(d)
|
v
SECURITIES PURCHASE AGREEMENT
– STANDARD TERMS
Recitals:
WHEREAS, the United States
Department of the Treasury (the “ Investor ”)
may from time to time agree to purchase shares of preferred stock
and warrants from eligible financial institutions which elect to
participate in the Troubled Asset Relief Program Capital Purchase
Program (“ CPP ”);
WHEREAS, an eligible financial
institution electing to participate in the CPP and issue securities
to the Investor (referred to herein as the “ Company
”) shall enter into a letter agreement (the “ Letter
Agreement ”) with the Investor which incorporates this
Securities Purchase Agreement – Standard Terms;
WHEREAS, the Company agrees to
expand the flow of credit to U.S. consumers and businesses on
competitive terms to promote the sustained growth and vitality of
the U.S. economy;
WHEREAS, the Company agrees to work
diligently, under existing programs, to modify the terms of
residential mortgages as appropriate to strengthen the health of
the U.S. housing market;
WHEREAS, the Company intends to
issue in a private placement the number of shares of the series of
its Preferred Stock (“ Preferred Stock ”) set
forth on Schedule A to the Letter Agreement (the “
Preferred Shares ”) and a warrant to purchase the
number of shares of its Common Stock (“ Common Stock
”) set forth on Schedule A to the Letter Agreement
(the “ Initial Warrant Shares ”) (the “
Warrant ” and, together with the Preferred Shares, the
“ Purchased Securities ”) and the Investor
intends to purchase (the “ Purchase ”) from the
Company the Purchased Securities; and
WHEREAS, the Purchase will be
governed by this Securities Purchase Agreement – Standard
Terms and the Letter Agreement, including the schedules thereto
(the “ Schedules ”), specifying additional terms
of the Purchase. This Securities Purchase Agreement –
Standard Terms (including the Annexes hereto) and the Letter
Agreement (including the Schedules thereto) are together referred
to as this “Agreement”. All references in this
Securities Purchase Agreement – Standard Terms to
“Schedules” are to the Schedules attached to the Letter
Agreement.
NOW, THEREFORE
, in consideration of the premises,
and of the representations, warranties, covenants and agreements
set forth herein, the parties agree as follows:
Article I
Purchase; Closing
1.1
Purchase . On the terms and subject to the conditions set
forth in this Agreement, the Company agrees to sell to the
Investor, and the Investor agrees to purchase from the Company, at
the Closing (as hereinafter defined), the Purchased Securities for
the price set forth on Schedule A (the “ Purchase
Price ”).
1.2
Closing .
(a)
On the terms and subject to the conditions set forth in this
Agreement, the closing of the Purchase (the “ Closing
”) will take place at the location specified in Schedule
A , at the time and on the date set forth in Schedule A
or as soon as practicable thereafter, or at such other place, time
and date as shall be agreed between the Company and the Investor.
The time and date on which the Closing occurs is referred to in
this Agreement as the “ Closing Date
”.
(b)
Subject to the fulfillment or waiver of the conditions to the
Closing in this Section 1.2, at the Closing the Company will
deliver the Preferred Shares and the Warrant, in each case as
evidenced by one or more certificates dated the Closing Date and
bearing appropriate legends as hereinafter provided for, in
exchange for payment in full of the Purchase Price by wire transfer
of immediately available United States funds to a bank account
designated by the Company on Schedule A .
(c)
The respective obligations of each of the Investor and the Company
to consummate the Purchase are subject to the fulfillment (or
waiver by the Investor and the Company, as applicable) prior to the
Closing of the conditions that (i) any approvals or
authorizations of all United States and other governmental,
regulatory or judicial authorities (collectively, “
Governmental Entities ”) required for the consummation
of the Purchase shall have been obtained or made in form and
substance reasonably satisfactory to each party and shall be in
full force and effect and all waiting periods required by United
States and other applicable law, if any, shall have expired and
(ii) no provision of any applicable United States or other law
and no judgment, injunction, order or decree of any Governmental
Entity shall prohibit the purchase and sale of the Purchased
Securities as contemplated by this Agreement.
(d)
The obligation of the Investor to consummate the Purchase is also
subject to the fulfillment (or waiver by the Investor) at or prior
to the Closing of each of the following conditions:
(i)
(A) the representations and warranties of the Company set
forth in (x) Section 2.2(g) of this Agreement shall
be true and correct in all respects as though made on and as of the
Closing Date, (y) Sections 2.2(a) through (f) shall
be true and correct in all material respects as though made on and
as of the Closing Date (other than representations and warranties
that by their terms speak as of another date, which representations
and warranties shall be true and correct in all material respects
as of such other date) and (z) Sections 2.2(h) through
(v) (disregarding all qualifications or limitations set forth
in such representations and warranties as to
“materiality”, “Company Material Adverse
Effect” and words of similar import) shall be true and
correct as though made on and as of the Closing Date (other than
representations and warranties that by their terms speak as of
another date, which representations and warranties shall be true
and correct as of such other date), except to the extent that the
failure of such representations and warranties referred to in this
Section 1.2(d)(i)(A)(z) to be so true and correct,
individually or in the aggregate, does not have and would not
reasonably be expected to have a Company Material Adverse Effect
and (B) the Company shall have
2
performed in all
material respects all obligations required to be performed by it
under this Agreement at or prior to the Closing;
(ii)
the Investor shall have received a certificate signed on behalf of
the Company by a senior executive officer certifying to the effect
that the conditions set forth in Section 1.2(d)(i) have
been satisfied;
(iii)
the Company shall have duly adopted and filed with the Secretary of
State of its jurisdiction of organization or other applicable
Governmental Entity the amendment to its certificate or articles of
incorporation, articles of association, or similar organizational
document (“ Charter ”) in substantially
the form attached hereto as Annex A (the “
Certificate of Designations ”) and such filing shall
have been accepted;
(iv)
(A) the Company shall have effected such changes to its
compensation, bonus, incentive and other benefit plans,
arrangements and agreements (including golden parachute, severance
and employment agreements) (collectively, “ Benefit
Plans ”) with respect to its Senior Executive Officers
(and to the extent necessary for such changes to be legally
enforceable, each of its Senior Executive Officers shall have duly
consented in writing to such changes), as may be necessary, during
the period that the Investor owns any debt or equity securities of
the Company acquired pursuant to this Agreement or the Warrant, in
order to comply with Section 111(b) of the Emergency
Economic Stabilization Act of 2008 (“ EESA ”) as
implemented by guidance or regulation thereunder that has been
issued and is in effect as of the Closing Date, and (B) the
Investor shall have received a certificate signed on behalf of the
Company by a senior executive officer certifying to the effect that
the condition set forth in Section 1.2(d)(iv)(A) has been
satisfied;
(v)
each of the Company’s Senior Executive Officers shall have
delivered to the Investor a written waiver in the form attached
hereto as Annex B releasing the Investor from any claims
that such Senior Executive Officers may otherwise have as a result
of the issuance, on or prior to the Closing Date, of any
regulations which require the modification of, and the agreement of
the Company hereunder to modify, the terms of any Benefit Plans
with respect to its Senior Executive Officers to eliminate any
provisions of such Benefit Plans that would not be in compliance
with the requirements of Section 111(b) of the EESA as
implemented by guidance or regulation thereunder that has been
issued and is in effect as of the Closing Date;
(vi)
the Company shall have delivered to the Investor a written opinion
from counsel to the Company (which may be internal counsel),
addressed to the Investor and dated as of the Closing Date, in
substantially the form attached hereto as Annex C
;
(vii)
the Company shall have delivered certificates in proper form or,
with the prior consent of the Investor, evidence of shares in
book-entry form, evidencing the Preferred Shares to Investor or its
designee(s); and
3
(viii)
the Company shall have duly executed the Warrant in substantially
the form attached hereto as Annex D and delivered such
executed Warrant to the Investor or its designee(s).
1.3
Interpretation
. When a reference is made in this
Agreement to “Recitals,” “Articles,”
“Sections,” or “Annexes” such reference
shall be to a Recital, Article or Section of, or Annex
to, this Securities Purchase Agreement – Standard Terms, and
a reference to “Schedules” shall be to a Schedule to
the Letter Agreement, in each case, unless otherwise indicated. The
terms defined in the singular have a comparable meaning when used
in the plural, and vice versa. References to “herein”,
“hereof”, “hereunder” and the like refer to
this Agreement as a whole and not to any particular section or
provision, unless the context requires otherwise. The table of
contents and headings contained in this Agreement are for reference
purposes only and are not part of this Agreement. Whenever the
words “include,” “includes” or
“including” are used in this Agreement, they shall be
deemed followed by the words “without limitation.” No
rule of construction against the draftsperson shall be applied
in connection with the interpretation or enforcement of this
Agreement, as this Agreement is the product of negotiation between
sophisticated parties advised by counsel. All references to
“$” or “dollars” mean the lawful currency
of the United States of America. Except as expressly stated in this
Agreement, all references to any statute, rule or regulation
are to the statute, rule or regulation as amended, modified,
supplemented or replaced from time to time (and, in the case of
statutes, include any rules and regulations promulgated under
the statute) and to any section of any statute, rule or
regulation include any successor to the section. References to a
“ business day ” shall mean any day except
Saturday, Sunday and any day on which banking institutions in the
State of New York generally are authorized or required by law or
other governmental actions to close.
Article II
Representations and
Warranties
2.1
Disclosure .
(a)
“ Company Material Adverse Effect ” means a
material adverse effect on (i) the business, results of
operation or financial condition of the Company and its
consolidated subsidiaries taken as a whole; provided ,
however , that Company Material Adverse Effect shall not be
deemed to include the effects of (A) changes after the date of
the Letter Agreement (the “ Signing Date ”) in
general business, economic or market conditions (including changes
generally in prevailing interest rates, credit availability and
liquidity, currency exchange rates and price levels or trading
volumes in the United States or foreign securities or credit
markets), or any outbreak or escalation of hostilities, declared or
undeclared acts of war or terrorism, in each case generally
affecting the industries in which the Company and its subsidiaries
operate, (B) changes or proposed changes after the Signing
Date in generally accepted accounting principles in the United
States (“ GAAP ”) or regulatory accounting
requirements, or authoritative interpretations thereof,
(C) changes or proposed changes after the Signing Date in
securities, banking and other laws of general applicability or
related policies or interpretations of Governmental Entities (in
the case of each of these clauses (A), (B) and (C), other than
changes
4
or occurrences to the extent
that such changes or occurrences have or would reasonably be
expected to have a materially disproportionate adverse effect on
the Company and its consolidated subsidiaries taken as a whole
relative to comparable U.S. banking or financial services
organizations), or (D) changes in the market price or trading
volume of the Common Stock or any other equity, equity-related or
debt securities of the Company or its consolidated subsidiaries (it
being understood and agreed that the exception set forth in this
clause (D) does not apply to the underlying reason giving rise
to or contributing to any such change); or (ii) the ability of
the Company to consummate the Purchase and the other transactions
contemplated by this Agreement and the Warrant and perform its
obligations hereunder or thereunder on a timely basis.
(b)
“
Previously Disclosed ” means information set forth or
incorporated in the Company’s Annual Report on Form 10-K
for the most recently completed fiscal year of the Company filed
with the Securities and Exchange Commission (the “ SEC
”) prior to the Signing Date (the “ Last Fiscal
Year ”) or in its other reports and forms filed with or
furnished to the SEC under Sections 13(a), 14(a) or
15(d) of the Securities Exchange Act of 1934 (the “
Exchange Act ”) on or after the last day of the Last
Fiscal Year and prior to the Signing Date.
2.2
Representations and Warranties of
the Company . Except as
Previously Disclosed, the Company represents and warrants to the
Investor that as of the Signing Date and as of the Closing Date (or
such other date specified herein):
(a)
Organization, Authority and Significant Subsidiaries . The
Company has been duly incorporated and is validly existing and in
good standing under the laws of its jurisdiction of organization,
with the necessary power and authority to own its properties and
conduct its business in all material respects as currently
conducted, and except as has not, individually or in the aggregate,
had and would not reasonably be expected to have a Company Material
Adverse Effect, has been duly qualified as a foreign corporation
for the transaction of business and is in good standing under the
laws of each other jurisdiction in which it owns or leases
properties or conducts any business so as to require such
qualification; each subsidiary of the Company that is a
“significant subsidiary” within the meaning of
Rule 1-02(w) of Regulation S-X under the Securities Act
of 1933 (the “ Securities Act ”) has been duly
organized and is validly existing in good standing under the laws
of its jurisdiction of organization. The Charter and bylaws
of the Company, copies of which have been provided to the Investor
prior to the Signing Date, are true, complete and correct copies of
such documents as in full force and effect as of the Signing
Date.
(b)
Capitalization . The authorized capital stock of the
Company, and the outstanding capital stock of the Company
(including securities convertible into, or exercisable or
exchangeable for, capital stock of the Company) as of the most
recent fiscal month-end preceding the Signing Date (the “
Capitalization Date ”) is set forth on Schedule
B . The outstanding shares of capital stock of the
Company have been duly authorized and are validly issued and
outstanding, fully paid and nonassessable, and subject to no
preemptive rights (and were not issued in violation of any
preemptive rights). Except as provided in the Warrant, as of the
Signing Date, the Company does not have outstanding any securities
or other obligations providing the holder the right to acquire
Common Stock that is not reserved for issuance as
5
specified on Schedule
B , and the Company has not made any other commitment to
authorize, issue or sell any Common Stock. Since the
Capitalization Date, the Company has not issued any shares of
Common Stock, other than (i) shares issued upon the exercise
of stock options or delivered under other equity-based awards or
other convertible securities or warrants which were issued and
outstanding on the Capitalization Date and disclosed on Schedule
B and (ii) shares disclosed on Schedule B
.
(c)
Preferred
Shares . The Preferred Shares have
been duly and validly authorized, and, when issued and delivered
pursuant to this Agreement, such Preferred Shares will be duly and
validly issued and fully paid and non-assessable, will not be
issued in violation of any preemptive rights, and will rank pari
passu with or senior to all other series or classes of
Preferred Stock, whether or not issued or outstanding, with respect
to the payment of dividends and the distribution of assets in the
event of any dissolution, liquidation or winding up of the
Company.
(d)
The Warrant
and Warrant Shares . The Warrant has been duly
authorized and, when executed and delivered as contemplated hereby,
will constitute a valid and legally binding obligation of the
Company enforceable against the Company in accordance with its
terms, except as the same may be limited by applicable bankruptcy,
insolvency, reorganization, moratorium or similar laws affecting
the enforcement of creditors’ rights generally and general
equitable principles, regardless of whether such enforceability is
considered in a proceeding at law or in equity (“
Bankruptcy Exceptions ”). The shares of Common Stock
issuable upon exercise of the Warrant (the “ Warrant
Shares ”) have been duly authorized and reserved for
issuance upon exercise of the Warrant and when so issued in
accordance with the terms of the Warrant will be validly issued,
fully paid and non-assessable, subject, if applicable, to the
approvals of its stockholders set forth on Schedule C
.
(e)
Authorization,
Enforceability .
(i)
The Company has the corporate power and authority to execute and
deliver this Agreement and the Warrant and, subject, if applicable,
to the approvals of its stockholders set forth on Schedule C
, to carry
out its obligations hereunder and thereunder (which includes the
issuance of the Preferred Shares, Warrant and Warrant Shares). The
execution, delivery and performance by the Company of this
Agreement and the Warrant and the consummation of the transactions
contemplated hereby and thereby have been duly authorized by all
necessary corporate action on the part of the Company and its
stockholders, and no further approval or authorization is required
on the part of the Company, subject, in each case, if applicable,
to the approvals of its stockholders set forth on Schedule C
. This Agreement is a valid and binding obligation of the Company
enforceable against the Company in accordance with its terms,
subject to the Bankruptcy Exceptions.
(ii)
The execution, delivery and performance by the Company of this
Agreement and the Warrant and the consummation of the transactions
contemplated hereby and thereby and compliance by the Company with
the provisions hereof and
6
thereof, will not
(A) violate, conflict with, or result in a breach of any
provision of, or constitute a default (or an event which, with
notice or lapse of time or both, would constitute a default) under,
or result in the termination of, or accelerate the performance
required by, or result in a right of termination or acceleration
of, or result in the creation of, any lien, security interest,
charge or encumbrance upon any of the properties or assets of the
Company or any Company Subsidiary under any of the terms,
conditions or provisions of (i) subject, if applicable, to the
approvals of the Company’s stockholders set forth on
Schedule C , its organizational documents or (ii) any
note, bond, mortgage, indenture, deed of trust, license, lease,
agreement or other instrument or obligation to which the Company or
any Company Subsidiary is a party or by which it or any Company
Subsidiary may be bound, or to which the Company or any Company
Subsidiary or any of the properties or assets of the Company or any
Company Subsidiary may be subject, or (B) subject to
compliance with the statutes and regulations referred to in the
next paragraph, violate any statute, rule or regulation or any
judgment, ruling, order, writ, injunction or decree applicable to
the Company or any Company Subsidiary or any of their respective
properties or assets except, in the case of clauses
(A)(ii) and (B), for those occurrences that, individually or
in the aggregate, have not had and would not reasonably be expected
to have a Company Material Adverse Effect.
(iii)
Other than the filing of the Certificate of Designations with the
Secretary of State of its jurisdiction of organization or other
applicable Governmental Entity, any current report on Form 8-K
required to be filed with the SEC, such filings and approvals as
are required to be made or obtained under any state “blue
sky” laws, the filing of any proxy statement
contemplated by Section 3.1 and such as have been made or
obtained, no notice to, filing with, exemption or review by, or
authorization, consent or approval of, any Governmental Entity is
required to be made or obtained by the Company in connection with
the consummation by the Company of the Purchase except for any such
notices, filings, exemptions, reviews, authorizations, consents and
approvals the failure of which to make or obtain would not,
individually or in the aggregate, reasonably be expected to have a
Company Material Adverse Effect.
(f)
Anti-takeover Provisions and Rights Plan . The Board
of Directors of the Company (the “ Board of Directors
”) has taken all necessary action to ensure that the
transactions contemplated by this Agreement and the Warrant and the
consummation of the transactions contemplated hereby and thereby,
including the exercise of the Warrant in accordance with its terms,
will be exempt from any anti-takeover or similar provisions of the
Company’s Charter and bylaws, and any other provisions of any
applicable “moratorium”, “control share”,
“fair price”, “interested stockholder” or
other anti-takeover laws and regulations of any jurisdiction.
The Company has taken all actions necessary to render any
stockholders’ rights plan of the Company inapplicable to this
Agreement and the Warrant and the consummation of the transactions
contemplated hereby and thereby, including the exercise of the
Warrant by the Investor in accordance with its terms.
(g)
No Company Material Adverse Effect . Since the last day of
the last completed fiscal period for which the Company has filed a
Quarterly Report on Form 10-Q or an Annual
7
Report on Form 10-K
with the SEC prior to the Signing Date, no fact, circumstance,
event, change, occurrence, condition or development has occurred
that, individually or in the aggregate, has had or would reasonably
be expected to have a Company Material Adverse Effect.
(h)
Company Financial
Statements . Each
of the consolidated financial statements of the Company and its
consolidated subsidiaries (collectively the “ Company
Financial Statements ”) included or incorporated by
reference in the Company Reports filed with the SEC since
December 31, 2006, present fairly in all material respects the
consolidated financial position of the Company and its consolidated
subsidiaries as of the dates indicated therein (or if amended prior
to the Signing Date, as of the date of such amendment) and the
consolidated results of their operations for the periods specified
therein; and except as stated therein, such financial statements
(A) were prepared in conformity with GAAP applied on a
consistent basis (except as may be noted therein), (B) have
been prepared from, and are in accordance with, the books and
records of the Company and the Company Subsidiaries and
(C) complied as to form, as of their respective dates of
filing with the SEC, in all material respects with the applicable
accounting requirements and with the published rules and
regulations of the SEC with respect thereto.
(i)
Reports .
(i)
Since December 31, 2006, the Company and each subsidiary of
the Company (each a “ Company Subsidiary ” and,
collectively, the “ Company Subsidiaries ”) has
timely filed all reports, registrations, documents, filings,
statements and submissions, together with any amendments thereto,
that it was required to file with any Governmental Entity (the
foregoing, collectively, the “ Company Reports
”) and has paid all fees and assessments due and payable in
connection therewith, except, in each case, as would not,
individually or in the aggregate, reasonably be expected to have a
Company Material Adverse Effect. As of their respective dates
of filing, the Company Reports complied in all material respects
with all statutes and applicable rules and regulations of the
applicable Governmental Entities. In the case of each such
Company Report filed with or furnished to the SEC, such Company
Report (A) did not, as of its date or if amended prior to the
Signing Date, as of the date of such amendment, contain an untrue
statement of a material fact or omit to state a material fact
necessary in order to make the statements made therein, in light of
the circumstances under which they were made, not misleading, and
(B) complied as to form in all material respects with the
applicable requirements of the Securities Act and the Exchange
Act. With respect to all other Company Reports, the Company
Reports were complete and accurate in all material respects as of
their respective dates. No executive officer of the Company
or any Company Subsidiary has failed in any respect to make the
certifications required of him or her under Section 302 or 906
of the Sarbanes-Oxley Act of 2002.
(ii)
The records, systems, controls, data and information of the Company
and the Company Subsidiaries are recorded, stored, maintained and
operated under means (including any electronic, mechanical or
photographic process, whether computerized or not) that are under
the exclusive ownership and direct control of the Company or
the
8
Company
Subsidiaries or their accountants (including all means of access
thereto and therefrom), except for any non-exclusive ownership and
non-direct control that would not reasonably be expected to have a
material adverse effect on the system of internal accounting
controls described below in this Section 2.2(i)(ii). The
Company (A) has implemented and maintains disclosure controls
and procedures (as defined in Rule 13a-15(e) of the
Exchange Act) to ensure that material information relating to the
Company, including the consolidated Company Subsidiaries, is made
known to the chief executive officer and the chief financial
officer of the Company by others within those entities, and
(B) has disclosed, based on its most recent evaluation prior
to the Signing Date, to the Company’s outside auditors and
the audit committee of the Board of Directors (x) any
significant deficiencies and material weaknesses in the design or
operation of internal controls over financial reporting (as defined
in Rule 13a-15(f) of the Exchange Act) that are
reasonably likely to adversely affect the Company’s ability
to record, process, summarize and report financial information and
(y) any fraud, whether or not material, that involves
management or other employees who have a significant role in the
Company’s internal controls over financial
reporting.
(j)
No Undisclosed Liabilities . Neither the Company nor
any of the Company Subsidiaries has any liabilities or obligations
of any nature (absolute, accrued, contingent or otherwise) which
are not properly reflected or reserved against in the Company
Financial Statements to the extent required to be so reflected or
reserved against in accordance with GAAP, except for
(A) liabilities that have arisen since the last fiscal year
end in the ordinary and usual course of business and consistent
with past practice and (B) liabilities that, individually or
in the aggregate, have not had and would not reasonably be expected
to have a Company Material Adverse Effect.
(k)
Offering of Securities . Neither the Company nor any
person acting on its behalf has taken any action (including any
offering of any securities of the Company under circumstances which
would require the integration of such offering with the offering of
any of the Purchased Securities under the Securities Act, and the
rules and regulations of the SEC promulgated thereunder),
which might subject the offering, issuance or sale of any of the
Purchased Securities to Investor pursuant to this Agreement to the
registration requirements of the Securities Act.
(l)
Litigation and Other Proceedings . Except (i) as
set forth on Schedule D or (ii) as would not,
individually or in the aggregate, reasonably be expected to have a
Company Material Adverse Effect, there is no (A) pending or,
to the knowledge of the Company, threatened, claim, action, suit,
investigation or proceeding, against the Company or any Company
Subsidiary or to which any of their assets are subject nor is the
Company or any Company Subsidiary subject to any order, judgment or
decree or (B) unresolved violation, criticism or exception by
any Governmental Entity with respect to any report or relating to
any examinations or inspections of the Company or any Company
Subsidiaries.
(m)
Compliance with Laws. Except as would not,
individually or in the aggregate, reasonably be expected to have a
Company Material Adverse Effect, the Company and the
9
Company Subsidiaries have
all permits, licenses, franchises, authorizations, orders and
approvals of, and have made all filings, applications and
registrations with, Governmental Entities that are required in
order to permit them to own or lease their properties and assets
and to carry on their business as presently conducted and that are
material to the business of the Company or such Company
Subsidiary. Except as set forth on Schedule E , the
Company and the Company Subsidiaries have complied in all respects
and are not in default or violation of, and none of them is, to the
knowledge of the Company, under investigation with respect to or,
to the knowledge of the Company, have been threatened to be charged
with or given notice of any violation of, any applicable domestic
(federal, state or local) or foreign law, statute, ordinance,
license, rule, regulation, policy or guideline, order, demand,
writ, injunction, decree or judgment of any Governmental Entity,
other than such noncompliance, defaults or violations that would
not, individually or in the aggregate, reasonably be expected to
have a Company Material Adverse Effect. Except for statutory
or regulatory restrictions of general application or as set forth
on Schedule E , no Governmental Entity has placed any
restriction on the business or properties of the Company or any
Company Subsidiary that would, individually or in the aggregate,
reasonably be expected to have a Company Material Adverse
Effect.
(n)
Employee Benefit Matters . Except as would not
reasonably be expected to have, either individually or in the
aggregate, a Company Material Adverse Effect: (A) each
“employee benefit plan” (within the meaning of
Section 3(3) of the Employee Retirement Income Security
Act of 1974, as amended (“ ERISA ”)) providing
benefits to any current or former employee, officer or director of
the Company or any member of its “ Controlled Group
” (defined as any organization which is a member of a
controlled group of corporations within the meaning of
Section 414 of the Internal Revenue Code of 1986, as amended
(the “ Code ”)) that is sponsored, maintained or
contributed to by the Company or any member of its Controlled Group
and for which the Company or any member of its Controlled Group
would have any liability, whether actual or contingent (each, a
“ Plan ”) has been maintained in compliance with
its terms and with the requirements of all applicable statutes,
rules and regulations, including ERISA and the Code;
(B) with respect to each Plan subject to Title IV of ERISA
(including, for purposes of this clause (B), any plan subject to
Title IV of ERISA that the Company or any member of its Controlled
Group previously maintained or contributed to in the six years
prior to the Signing Date), (1) no “reportable
event” (within the meaning of Section 4043(c) of
ERISA), other than a reportable event for which the notice
period referred to in Section 4043(c) of ERISA has been
waived, has occurred in the three years prior to the Signing Date
or is reasonably expected to occur, (2) no “accumulated
funding deficiency” (within the meaning of Section 302
of ERISA or Section 412 of the Code), whether or not waived,
has occurred in the three years prior to the Signing Date or is
reasonably expected to occur, (3) the fair market value of the
assets under each Plan exceeds the present value of all benefits
accrued under such Plan (determined based on the assumptions used
to fund such Plan) and (4) neither the Company nor any member
of its Controlled Group has incurred in the six years prior to the
Signing Date, or reasonably expects to incur, any liability under
Title IV of ERISA (other than contributions to the Plan or premiums
to the PBGC in the ordinary course and without default) in respect
of a Plan (including any Plan that is a “multiemployer
plan”, within the meaning of Section 4001(c)(3) of
ERISA); and (C) each Plan that is intended to be qualified
under Section 401(a) of the Code has received a
favorable
10
determination letter from the Internal Revenue
Service with respect to its qualified status that has not been
revoked, or such a determination letter has been timely applied for
but not received by the Signing Date, and nothing has occurred,
whether by action or by failure to act, which could reasonably be
expected to cause the loss, revocation or denial of such qualified
status or favorable determination letter.
(o)
Taxes . Except as would not, individually or in the
aggregate, reasonably be expected to have a Company Material
Adverse Effect, (i) the Company and the Company Subsidiaries
have filed all federal, state, local and foreign income and
franchise Tax returns required to be filed through the Signing
Date, subject to permitted extensions, and have paid all Taxes due
thereon, and (ii) no Tax deficiency has been determined
adversely to the Company or any of the Company Subsidiaries, nor
does the Company have any knowledge of any Tax deficiencies.
“ Tax ” or “ Taxes ” means
any federal, state, local or foreign income, gross receipts,
property, sales, use, license, excise, franchise, employment,
payroll, withholding, alternative or add on minimum, ad valorem,
transfer or excise tax, or any other tax, custom, duty,
governmental fee or other like assessment or charge of any kind
whatsoever, together with any interest or penalty, imposed by any
Governmental Entity.
(p)
Properties and Leases . Except as would not, individually or
in the aggregate, reasonably be expected to have a Company Material
Adverse Effect, the Company and the Company Subsidiaries have good
and marketable title to all real properties and all other
properties and assets owned by them, in each case free from liens,
encumbrances, claims and defects that would affect the value
thereof or interfere with the use made or to be made thereof by
them. Except as would not, individually or in the aggregate,
reasonably be expected to have a Company Material Adverse Effect,
the Company and the Company Subsidiaries hold all leased real or
personal property under valid and enforceable leases with no
exceptions that would interfere with the use made or to be made
thereof by them.
(q)
Environmental Liability . Except as would not, individually
or in the aggregate, reasonably be expected to have a Company
Material Adverse Effect:
(i)
there is no legal, administrative, or other proceeding, claim or
action of any nature seeking to impose, or that would reasonably be
expected to result in the imposition of, on the Company or any
Company Subsidiary, any liability relating to the release of
hazardous substances as defined under any local, state or federal
environmental statute, regulation or ordinance, including the
Comprehensive Environmental Response, Compensation and Liability
Act of 1980, pending or, to the Company’s knowledge,
threatened against the Company or any Company
Subsidiary;
(ii)
to the Company’s knowledge, there is no reasonable basis for
any such proceeding, claim or action; and
(iii)
neither the Company nor any Company Subsidiary is subject to any
agreement, order, judgment or decree by or with any court,
Governmental Entity or third party imposing any such environmental
liability.
11
(r)
Risk Management Instruments . Except as would not,
individually or in the aggregate, reasonably be expected to have a
Company Material Adverse Effect, all derivative instruments,
including, swaps, caps, floors and option agreements, whether
entered into for the Company’s own account, or for the
account of one or more of the Company Subsidiaries or its or their
customers, were entered into (i) only in the ordinary course
of business, (ii) in accordance with prudent practices and in
all material respects with all applicable laws, rules, regulations
and regulatory policies and (iii) with counterparties believed
to be financially responsible at the time; and each of such
instruments constitutes the valid and legally binding obligation of
the Company or one of the Company Subsidiaries, enforceable in
accordance with its terms, except as may be limited by the
Bankruptcy Exceptions. Neither the Company or the Company
Subsidiaries, nor, to the knowledge of the Company, any other party
thereto, is in breach of any of its obligations under any such
agreement or arrangement other than such breaches that would not,
individually or in the aggregate, reasonably be expected to have a
Company Material Adverse Effect.
(s)
Agreements with Regulatory Agencies . Except as set
forth on Schedule F , neither the Company nor any Company
Subsidiary is subject to any material cease-and-desist or other
similar order or enforcement action issued by, or is a party to any
material written agreement, consent agreement or memorandum of
understanding with, or is a party to any commitment letter or
similar undertaking to, or is subject to any capital directive by,
or since December 31, 2006, has adopted any board resolutions
at the request of, any Governmental Entity (other than the
Appropriate Federal Banking Agencies with jurisdiction over the
Company and the Company Subsidiaries) that currently restricts in
any material respect the conduct of its business or that in any
material manner relates to its capital adequacy, its liquidity and
funding policies and practices, its ability to pay dividends, its
credit, risk management or compliance policies or procedures, its
internal controls, its management or its operations or business
(each item in this sentence, a “ Regulatory Agreement
”), nor has the Company or any Company Subsidiary been
advised since December 31, 2006 by any such Governmental
Entity that it is considering issuing, initiating, ordering, or
requesting any such Regulatory Agreement. The Company and
each Company Subsidiary are in compliance in all material respects
with each Regulatory Agreement to which it is party or subject, and
neither the Company nor any Company Subsidiary has received any
notice from any Governmental Entity indicating that either the
Company or any Company Subsidiary is not in compliance in all
material respects with any such Regulatory Agreement. “
Appropriate Federal Banking Agency ” means the
“appropriate Federal banking agency” with respect to
the Company or such Company Subsidiaries, as applicable, as defined
in Section 3(q) of the Federal Deposit Insurance Act (12
U.S.C. Section 1813(q)).
(t)
Insurance . The Company and the Company Subsidiaries
are insured with reputable insurers against such risks and in such
amounts as the management of the Company reasonably has determined
to be prudent and consistent with industry practice. The
Company and the Company Subsidiaries are in material compliance
with their insurance policies and are not in default under any of
the material terms thereof, each such policy is outstanding and in
full force and effect, all premiums and other payments due under
any material policy have been paid, and all claims thereunder have
been filed in due and timely fashion, except, in each case, as
would not, individually or in the aggregate, reasonably be expected
to have a Company Material Adverse Effect.
12
(u)
Intellectual Property . Except as would not,
individually or in the aggregate, reasonably be expected to
have a Company Material Adverse Effect, (i) the Company and
each Company Subsidiary owns or otherwise has the right to use, all
intellectual property rights, including all trademarks, trade
dress, trade names, service marks, domain names, patents,
inventions, trade secrets, know-how, works of authorship and
copyrights therein, that are used in the conduct of their existing
businesses and all rights relating to the plans, design and
specifications of any of its branch facilities (“
Proprietary Rights ”) free and clear of all liens and
any claims of ownership by current or former employees,
contractors, designers or others and (ii) neither the Company
nor any of the Company Subsidiaries is materially infringing,
diluting, misappropriating or violating, nor has the Company or any
or the Company Subsidiaries received any written (or, to the
knowledge of the Company, oral) communications alleging that any of
them has materially infringed, diluted, misappropriated or
violated, any of the Proprietary Rights owned by any other
person. Except as would not, individually or in the
aggregate, reasonably be expected to have a Company Material
Adverse Effect, to the Company’s knowledge, no other person
is infringing, diluting, misappropriating or violating, nor has the
Company or any or the Company Subsidiaries sent any written
communications since January 1, 2006 alleging that any person
has infringed, diluted, misappropriated or violated, any of the
Proprietary Rights owned by the Company and the Company
Subsidiaries.
(v)
Brokers and Finders . No broker, finder or investment
banker is entitled to any financial advisory, brokerage,
finder’s or other fee or commission in connection with this
Agreement or the Warrant or the transactions contemplated hereby or
thereby based upon arrangements made by or on behalf of the Company
or any Company Subsidiary for which the Investor could have any
liability.
Article III
Covenants
3.1
Commercially Reasonable Efforts .
(a)
Subject to the terms and conditions of this Agreement, each of the
parties will use its commercially reasonable efforts in good faith
to take, or cause to be taken, all actions, and to do, or cause to
be done, all things necessary, proper or desirable, or advisable
under applicable laws, so as to permit consummation of the Purchase
as promptly as practicable and otherwise to enable consummation of
the transactions contemplated hereby and shall use commercially
reasonable efforts to cooperate with the other party to that
end.
(b)
If the Company is required to obtain any stockholder approvals set
forth on Schedule C , then the Company shall comply with
this Section 3.1(b) and Section 3.1(c). The Company
shall call a special meeting of its stockholders, as promptly as
practicable following the Closing, to vote on proposals
(collectively, the “ Stockholder Proposals ”) to
(i) approve the exercise of the Warrant for Common Stock for
purposes of the rules of the national security exchange on
which the Common Stock is listed and/or (ii) amend the
Company’s Charter to increase the number of
authorized shares of Common Stock to at least such number as shall
be sufficient to permit the full exercise of the Warrant for Common
Stock and comply with the
13
other provisions of this
Section 3.1(b) and Section 3.1(c). The Board of
Directors shall recommend to the Company’s stockholders that
such stockholders vote in favor of the Stockholder Proposals.
In connection with such meeting, the Company shall prepare (and the
Investor will reasonably cooperate with the Company to prepare) and
file with the SEC as promptly as practicable (but in no event more
than ten business days after the Closing) a preliminary proxy
statement, shall use its reasonable best efforts to respond to any
comments of the SEC or its staff thereon and to cause a definitive
proxy statement related to such stockholders’ meeting to be
mailed to the Company’s stockholders not more than five
business days after clearance thereof by the SEC, and shall use its
reasonable best efforts to solicit proxies for such stockholder
approval of the Stockholder Proposals. The Company shall
notify the Investor promptly of the receipt of any comments from
the SEC or its staff with respect to the proxy statement and of any
request by the SEC or its staff for amendments or supplements to
such proxy statement or for additional information and will supply
the Investor with copies of all correspondence between the Company
or any of its representatives, on the one hand, and the SEC or its
staff, on the other hand, with respect to such proxy
statement. If at any time prior to such stockholders’
meeting there shall occur any event that is required to be set
forth in an amendment or supplement to the proxy statement, the
Company shall as promptly as practicable prepare and mail to its
stockholders such an amendment or supplement. Each of the
Investor and the Company agrees promptly to correct any information
provided by it or on its behalf for use in the proxy statement if
and to the extent that such information shall have become false or
misleading in any material respect, and the Company shall as
promptly as practicable prepare and mail to its stockholders an
amendment or supplement to correct such information to the extent
required by applicable laws and regulations. The Company
shall consult with the Investor prior to filing any proxy
statement, or any amendment or supplement thereto, and provide the
Investor with a reasonable opportunity to comment thereon. In
the event that the approval of any of the Stockholder Proposals is
not obtained at such special stockholders meeting, the Company
shall include a proposal to approve (and the Board of Directors
shall recommend approval of) each such proposal at a meeting of its
stockholders no less than once in each subsequent six-month period
beginning on January 1, 2009 until all such approvals are
obtained or made.
(c)
None of the information supplied by
|